Current Appointments & Affiliations
Instructor in the Department of Medicine
·
2020 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2022 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Journal Article Oncologist · November 11, 2025 BACKGROUND: Erdafitinib is approved for locally advanced/metastatic urothelial cancer (LA/mUC). As enfortumab vedotin (EV) plus pembrolizumab enters frontline management, outcomes with erdafitinib pre- and post-EV are clinically relevant but not specifical ... Full text Link to item CiteAbstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)
Conference Molecular Cancer Therapeutics · October 22, 2025 AbstractBackground:XmAb819 is a T-cell engaging bispecific antibody in development for patients with ccRCC. Despite advances in ... Full text CitePhase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Journal Article Clin Cancer Res · October 1, 2025 PURPOSE: Nelitolimod (previously SD-101) is a toll-like receptor 9 agonist. We assessed whether intratumoral nelitolimod plus pembrolizumab potentiates antitumor activity in patients with advanced melanoma who had not previously received anti-PD-1/PD-L1 th ... Full text Link to item CiteRecent Grants
GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients with Solid Tumors that Harbor the p53 R175H Mutation
Clinical TrialPrincipal Investigator · Awarded by Clasp Therapeutics, Inc · 2025 - 2030A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2025 - 2030A Phase 2, Randomized, Double-blind, Placebo- and Active-comparator-controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcino
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2024 - 2029View All Grants
Education, Training & Certifications
New York Institute of Technology, College of Osteopathic Medicine ·
2001
D.O.